Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-07-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainmetastaticcancerpancreatictherapy
  Phrases that lowered it: solidovariantumorstrialopen label
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Keywords listed: 23 (raises risk) · Design
• Drug's FAERS reports marked serious: 95.4% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 20.4% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: sequential (lowers risk) · Design
• Sponsor's past trials: 5 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 108147 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 12722 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors NCT05262530 · started 2022 · scored riskier than 33% of active trials terminated
• Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 NCT05980416 · started 2023 · scored riskier than 77% of active trials terminated
• Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors NCT04400383 · started 2020 · scored riskier than 17% of active trials completed
• A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications NCT05317078 · started 2023 · scored riskier than 40% of active trials terminated
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 NCT05199519 · started 2021 · scored riskier than 16% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.